HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Stocks News ETF News Crypto News

Cytokinetics, Incorporated

Contributing Author

Recent Articles by Cytokinetics, Incorporated

Oct-31
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 CYTK GlobeNewswire
Oct-22
Cytokinetics to Announce Third Quarter Results on November 5, 2025 CYTK GlobeNewswire
Oct-17
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) CYTK GlobeNewswire
Sep-29
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025 CYTK GlobeNewswire
Sep-24
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program CYTK GlobeNewswire
Sep-23
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum CYTK GlobeNewswire
Sep-18
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) CYTK GlobeNewswire
Sep-18
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 CYTK GlobeNewswire
Sep-16
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes CYTK GlobeNewswire
Sep-16
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes CYTK GlobeNewswire
Aug-31
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 CYTK GlobeNewswire
Aug-30
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine CYTK GlobeNewswire
Aug-27
Cytokinetics to Participate in September Investor Conferences CYTK GlobeNewswire
Aug-25
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 CYTK GlobeNewswire
Aug-20
Cytokinetics Names Jim Daly to Board of Directors CYTK GlobeNewswire
Aug-19
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CYTK GlobeNewswire
Aug-07
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update CYTK GlobeNewswire
Jul-24
Cytokinetics to Announce Second Quarter Results On August 7, 2025 CYTK GlobeNewswire
Jul-18
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) CYTK GlobeNewswire
Jul-10
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 CYTK GlobeNewswire
Jun-17
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CYTK GlobeNewswire
Jun-10
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program CYTK GlobeNewswire
May-29
Cytokinetics to Participate in the Jefferies Global Healthcare Conference CYTK GlobeNewswire
May-18
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress CYTK GlobeNewswire
May-16
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CYTK GlobeNewswire
May-15
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology CYTK GlobeNewswire
May-13
Cytokinetics Announces Positive Topline Results From MAPLE-HCM CYTK GlobeNewswire
May-08
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress CYTK GlobeNewswire
May-07
Cytokinetics to Hold Annual Meeting of Stockholders CYTK GlobeNewswire
May-06
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update CYTK GlobeNewswire
May-01
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy CYTK GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.